Clinical trial
A Multi-cohort, Open-label, Multicenter Exploratory Clinical Study of Bemalenograstim Alfa for the Prevention of Reduced ANC in Patients With Colorectal Cancer/Pancreatic Cancer Following a Bi-weekly Chemotherapy
NCT06134765 is registered in ClinicalTrials.gov with Second Affiliated Hospital, Zhejiang University, School of Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-cohort, Open-label, Multicenter Exploratory Clinical Study of Bemalenograstim Alfa for the Prevention of Reduced ANC in Patients With Colorectal Cancer/Pancreatic Cancer Following a Bi-weekly Chemotherapy
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- November 30, 2023
- Completion date
- March 30, 2025
- Enrollment
- 89 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
colorectal cancer, pancreatic cancer